A case is described of a 19-year-old man with poor prognosis intra-abdominal desmoplastic small round cell tumor, who achieved a durable complete remission after aggressive multimodality treatment. He was diagnosed with a large peri-rectal mass and bulky metastases to the peritoneum, omentum and liver. He achieved a partial response to six courses of chemotherapy with VAC (vincristine, adriamycin, actinomycin, cyclophosphamide) and VIP (VP-16, ifosfamide, cisplatin). This was followed by resection of the omentum and cryotherapy to six of the liver lesions. He then achieved a complete response following high-dose busulfan 16 mg/kg and melphalan 140 mg/m 2 with autologous stem cell support. Finally, pelvic radiotherapy was given to consolidate the remission. Twenty-six months following his diagnosis, and 19 months after the transplant, he remains well with no clinical or radiologic evidence of recurrent disease. This case report suggests a role for autologous stem cell transplantation as part of multimodality therapy for this unusual and aggressive malignancy.
Intra-abdominal desmoplastic small round cell tumor (DSRCT) is a recently described, uncommon entity.
1,2 It occurs predominantly in young males without any other apparent risk factors. It presents most commonly with gastrointestinal obstructive symptoms, abdominal pain, and an abdominal mass. Typically, there is a large intra-abdominal mass associated with smaller peritoneal implants. Histologically, nests of small round tumor cells which coexpress both epithelial and mesenchymal markers are surrounded by a cellular desmoplastic stroma. 1, 2 Unfortunately, these aggressive tumors are usually incurable despite various combinations of surgery, radiotherapy, and standard-dose chemotherapy. Of the previously reported cases in the literature, there is a median survival of 15 months [1] [2] [3] [4] [5] [6] with rare patients surviving for more than 5 years. 4 Therefore, more effective therapy for these patients is needed. We report a patient with metastatic intra-abdominal DSRCT who received aggressive multimodality therapy including high-dose chemotherapy and autologous stem cell support.
Case report
A 19-year-old man presented in May 1995 with a 6 week history of constipation, drenching night sweats, vague abdominal discomfort, and a 25 pound weight loss. An anterior mass was palpable on rectal examination. An abdominal/pelvic CT scan revealed bulky disease with multiple liver metastases up to 5 cm in diameter, a 6 × 8 cm omental mass, and an anterior peri-rectal mass also measuring 6 × 8 cm (Figure 1) . A CT-guided core biopsy demonstrated a poorly differentiated malignant neoplasm which stained positively for vimentin and cytokeratin but negatively with neural stains. The exact diagnosis was initially uncertain. From June to October 1995, the patient received four cycles of VAC (vincristine, adriamycin, actinomycin D, cyclophosphamide) and two cycles of VIP (VP-16, ifosfamide, cisplatin). This protocol is used at our centre for small round cell sarcomas such as Ewing's sarcoma. He had significant symptomatic improvement with resolution of sweats and abdominal pain, and stabilization of weight. A repeat CT scan demonstrated that the maximal diameters of the omental and peri-rectal masses had decreased to 5 cm and 4 cm, respectively, and that the liver metastases had also responded.
In November 1995, he underwent laparotomy, omentectomy, cryotherapy to six intrahepatic metastases and insertion of a pelvic tissue expander. The peri-rectal mass was left in situ, as were the numerous peritoneal seedlings found at surgery. Pathology of the surgical specimen was extensively reviewed and revealed uniform small cells with small nucleoli and numerous spindle areas. The tumor was high grade and stained strongly positive for keratin and desmin and moderately positive for vimentin and smooth muscle actin ( Figure 2 ). These features were thought to be most consistent with an intra-abdominal desmoplastic small round cell tumor.
In early January 1996, the patient underwent autologous blood stem cell transplantation after conditioning with busulfan 16 mg/kg and melphalan 140 mg/m 2 . This regimen was chosen because it is very active in the treatment of Ewing's sarcoma, another small round cell tumor. 7 He had no Bearman grade III or IV regimen-related toxicities. 8 A CT scan in February 1996 demonstrated complete resolution of the peri-rectal mass. Only two dominant hepatic abnormalities were visible and they had both decreased in size. In February and March 1996 he received 4500 cGy adjuvant radiation to the pelvis. This patient has been followed regularly both clinically and with serial CT scans. As of August 1997, he remains in good general health with no evidence of recurrent disease.
Discussion
DSRCT present both a diagnostic and a therapeutic challenge. Several series of related cases have been described but its true frequency is unknown. Histologically, these tumors are small round cell tumors, similar in appearance to Ewing's sarcoma, rhabdomyosarcoma, small cell lymphoma, small cell carcinoma and neuroblastoma. These tumors are all characterized by high cellularity, small cell size, and diffuse growth pattern. Since the development of immunohistochemical stains, DSRCT have emerged as a separate entity from other small round cell tumors. A large panel of antibodies must be used to ensure that the diagnosis is not overlooked. They are usually desmin, keratin, and vimentin positive. The desmin and vimentin staining is primarily paranuclear, with keratin staining distributed throughout the cytoplasm. Recently, a chromosome translocation t(11;22)(p13;q12) has been associated with DSRCT and is thought to be responsible for the multi-immunophenotypic differentiation. 2, 5 Primary treatment has consisted of aggressive debulking surgery followed by chemotherapy and/or radiation. Typically, an initial response to chemotherapy is followed by uncontrolled tumor recurrence. Exact response rates cannot be determined from the majority of reports, and the cases are difficult to compare because of the variety of chemotherapy regimens utilized. Adriamycin and/or cisplatin appear to be associated with comparatively longer survivals with a range of 8-48 months. 1 A few cases treated with high-dose chemotherapy and autologous stem cell support have been reported to date. Ordonez et al 3 described the case of a 28-year-old man with intra-abdominal DSRCT treated with aggressive surgery, extensive cisplatin/adriamycin-based chemotherapy, and high-dose dacarbazine and autologous bone marrow transplant. Length of response is not clear from this report, but the patient succumbed to extensive tumor recurrence within 2 years of initial diagnosis.
More recently, Kushner et al 6 described prolonged progression-free survival with aggressive multimodality therapy. All patients received four courses of intensive vincristine/adriamycin/cyclophosphamide and three courses of ifosfamide/etoposide. Chemotherapy was followed by maximum surgical resection and, in most cases, consolidation therapy in the form of either radiation to high-risk sites, or high-dose chemotherapy and autologous bone marrow transplantation. Since a further response to high-dose therapy was not described in any of these patients, it is unclear whether or not this consolidative approach significantly affected progression-free or overall survival.
The 19-year-old man described in this case report is unique because the partial response he achieved to aggressive surgery and chemotherapy was followed by a definite further response to high-dose chemotherapy and autologous stem cell transplantation. High-dose busulfan and melphalan chemotherapy was a significant component of the multimodality approach and should be explored further in the treatment of this unusual and aggressive malignancy. This case demonstrates that intra-abdominal DSRCT can be successfully treated with a systematic and timely application of aggressive multimodality interventions, and that high-dose chemotherapy may be a necessary part of this therapeutic approach for some patients.
